ORTIN GLOBAL enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


10.1	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.6	0.6	0.4	0.5	0.2
1.0	1.0	0.3	1.8	6.4
10.5	—	—	—	—
0.4	0.4	−0.1	1.3	6.2
₹12.90	—	—	—	—

2.2	2.2	2.2	4.6	17.3
44.8%	44.8%	11.2%	39.0%	37.2%
0.10×	—	—	—	—

145.13×	—	—	—	—
−8.97×	—	—	—	—
−8.96×	—	—	—	—
0.1	0.1	0.3	2.1	6.0
−1.2	−1.0	−0.9	−6.5	0.5
−1.2	−1.0	−0.9	−6.8	0.3
—	−0.6	−0.4	−3.7	−0.2
−0.6	−0.6	−0.4	−3.7	−0.2
—	−0.6	−0.4	−3.7	−0.3
—	0.0	0.0	0.0	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ORTINGLOBE₹12.41

ORTIN GLOBAL LIMITED

· Pharma & Health

₹ CrorePeersLASA MANGALAM BIOFILCHEM VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹10.1 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	10.1
- Cash, Equiv & ST Investments	0.2	0.5	0.4	0.6	0.6
+ Total Debt	6.4	1.8	0.3	1.0	1.0
Enterprise Value	—	—	—	—	10.5
Net Debt (memo)	6.2	1.3	-0.1	0.4	0.4
EV per Share	—	—	—	—	12.90

Total Capital	17.3	4.6	2.2	2.2	2.2
Total Debt/Total Capital	37.24	38.96	11.22	44.82	44.82
Total Debt/EV	—	—	—	—	0.10

EV/Sales	—	—	—	—	145.13
EV/EBITDA	—	—	—	—	-8.97
EV/EBIT	—	—	—	—	-8.96
Reference Items — Trailing FY Values
Sales	6.0	2.1	0.3	0.1	0.1
EBITDA	0.5	-6.5	-0.9	-1.0	-1.2
EBIT	0.3	-6.8	-0.9	-1.0	-1.2
Operating Cash Flow	-0.2	-3.7	-0.4	-0.6	—
Free Cash Flow	-0.2	-3.7	-0.4	-0.6	-0.6
FCFF (free cash flow to the firm)	-0.3	-3.7	-0.4	-0.6	—
Capital Expenditure	0.0	0.0	0.0	0.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.